Optum and Illumina Inc. researchers documented that less than half of patients with newly diagnosed advanced cancers received any biomarker testing before starting treatment, a gap that persisted ...

We performed a single-institution, retrospective analysis of CGP utilization and treatment patterns in patients with localized PDAC who underwent curative-intent resection in the contemporary period ...

A real-world analysis found that comprehensive genomic profiling (CGP) in patients with non–small cell lung cancer (NSCLC) increases their therapy options patients and CGP testing needs to be utilized ...

Genomic Testing Cooperative (GTC) today highlighted its Liquid Trace® cerebrospinal fluid (CSF)-based molecular profiling ...

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) regarding characterization and treatment of central nervous system (CNS) cancers were very recently updated and have expanded the ...

CGP identifies TP53 and SMAD4 mutations as negative prognostic markers, while PTEN mutations correlate with improved survival in CRC patients. Despite no significant survival advantage, CGP-guided ...

A CGP assay that detects more than 700 cancer-relevant gene variants and molecular signatures, gives researchers new insights into tumour biology, expanding the potential for personalized cancer ...

“The broad capabilities of the OncoExTra assay detected therapeutically actionable and other clinically relevant genomic events that can inform clinical decision-making for patients with advanced ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision ...

The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the launch of JAYseq TM, a clinical whole-genome sequencing (WGS) test specifically for multiple myeloma.